Search Result

Results for "

MAO

" in MCE Product Catalog:

By Targets:	Monoamine Oxidase (132) 5-HT Receptor (3) Adenosine Receptor (1) Adrenergic Receptor (3) Amyloid-β (5) Antibiotic (1) Apoptosis (4) Autophagy (2) Cholinesterase (ChE) (17) COMT (7) Cytochrome P450 (2) Dopamine Transporter (1) Dopamine β-hydroxylase (2) Endogenous Metabolite (3) Enterovirus (2) Estrogen Receptor/ERR (1) Guanylate Cyclase (3) HDAC (3) HIF/HIF Prolyl-Hydroxylase (1) Histone Demethylase (15) HSV (1) iGluR (1) Imidazoline Receptor (3) Influenza Virus (1) mGluR (2) Microtubule/Tubulin (2) NO Synthase (3) Parasite (1) PKC (1) Reactive Oxygen Species (1) Reverse Transcriptase (1) Telomerase (1)
By Research Areas:	Cancer (28) Cardiovascular Disease (11) Endocrinology (3) Infection (8) Inflammation/Immunology (5) Metabolic Disease (4) Neurological Disease (116)

By Targets:

Monoamine Oxidase (132)

5-HT Receptor (3)

Adenosine Receptor (1)

Adrenergic Receptor (3)

Amyloid-β (5)

Antibiotic (1)

Apoptosis (4)

Autophagy (2)

Cholinesterase (ChE) (17)

COMT (7)

Cytochrome P450 (2)

Dopamine Transporter (1)

Dopamine β-hydroxylase (2)

Endogenous Metabolite (3)

Enterovirus (2)

Estrogen Receptor/ERR (1)

Guanylate Cyclase (3)

HDAC (3)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Demethylase (15)

HSV (1)

iGluR (1)

Imidazoline Receptor (3)

Influenza Virus (1)

mGluR (2)

Microtubule/Tubulin (2)

NO Synthase (3)

Parasite (1)

PKC (1)

Reactive Oxygen Species (1)

Reverse Transcriptase (1)

Telomerase (1)

By Research Areas:

Cancer (28)

Cardiovascular Disease (11)

Endocrinology (3)

Infection (8)

Inflammation/Immunology (5)

Metabolic Disease (4)

Neurological Disease (116)

147

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Monoamine Oxidase

Cat. No.	Product Name	Target	Research Areas

HY-142706

MAO A/HDAC-IN-1
Monoamine Oxidase HDAC Cancer

MAO A/HDAC-IN-1 is a dual inhibitor of monoamine oxidase A (MAO A) and HDAC. MAO A/HDAC-IN-1 can be used for glioma research.
HY-U00015

MAO-IN-1
Monoamine Oxidase Neurological Disease

MAO-IN-1 is a monoamine oxidase B (MAO B) inhibitor with an IC₅₀ of 20 nM.

MAO A/HDAC-IN-1	Monoamine Oxidase HDAC	Cancer
MAO A/HDAC-IN-1 is a dual inhibitor of *monoamine oxidase A (MAO* A) and HDAC*. MAO* A/HDAC-IN-1 can be used for glioma research.

MAO-IN-1	Monoamine Oxidase	Neurological Disease
MAO-IN-1 is a monoamine oxidase B (MAO B) inhibitor with an IC₅₀ of 20 nM.

HY-151800

MAO-A/B-IN-2	Monoamine Oxidase	Neurological Disease
MAO-A/B-IN-2 (compound 30) is a *MAO-A/B* inhibitor with IC₅₀ values of 17.8 and 15.8 μM for *MAO-A* and *MAO-B, respectively. MAO*-A/B-IN-2 can be used in the study of neurological disorders.

HY-131036

MAO-IN-M30 dihydrochloride	Monoamine Oxidase	Neurological Disease
MAO-IN-M30 dihydrochloride is an orally active, brain-permeable, and brain selective irreversible *MAO-A* (IC₅₀=37 nM) and *MAO-B* (IC₅₀=57 nM) inhibitor. MAO-IN-M30 dihydrochloride is a potent iron chelator and radical scavenger. MAO-IN-M30 dihydrochloride has a neuroprotective effect against Dexamethasone-induced brain cell apoptosis. MAO-IN-M30 dihydrochloride also exhibits neurorestorative activity in post MPTP and lactacystin models of Parkinson's disease.

HY-147362

MAO-B-IN-14	Monoamine Oxidase	Neurological Disease
MAO-B-IN-14 (Compound 9) is a potent and selective monoamine oxidase-B (MAO-B) inhibitor with an IC₅₀ of 0.95 μM and a K_i of 0.55 μM against human MAO-B.

HY-146958

MAO-B-IN-8	Monoamine Oxidase	Neurological Disease
MAO-B-IN-8 is a potent reversible *MAO-B* inhibitor and an inhibitor of microglial production of neuroinflammatory mediator. MAO-B-IN-8 can be used for neurodegenerative disease research.

HY-115987

MAO-B-IN-6	Monoamine Oxidase	Neurological Disease
MAO-B-IN-6 is a potent, selective and orally active *MAO-B* inhibitor with an IC₅₀ of 0.019 µM. MAO-B-IN-6 shows more efficacious than Safinamide in vitro and in vivo. MAO-B-IN-6 has the potential for the research of parkinson's disease (PD).

HY-147953

MAO-B-IN-13	Monoamine Oxidase	Neurological Disease
MAO-B-IN-13 (compound 12a) is a highly potent, reversible and blood-brain barrier (BBB) penetrant *MAO-B* inhibitor with an IC₅₀ value of 10 nM. MAO-B-IN-13 has neuroprotective and antioxidant activity. MAO-B-IN-13 can be used for researching Parkinson’s disease.

HY-146149

MAO-B-IN-11	Monoamine Oxidase	Neurological Disease
MAO-B-IN-11 (Compound 8c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-11 shows a neuroprotective activity.

HY-115986

MAO-B-IN-5	Monoamine Oxidase	Neurological Disease
MAO-B-IN-5 is a potent, selective and orally active *MAO-B* inhibitor with an IC₅₀ of 0.204 µM. MAO-B-IN-5 has the potential for the research of Parkinson's disease (PD).

HY-146150

MAO-B-IN-12	Monoamine Oxidase	Neurological Disease
MAO-B-IN-12 (Compound 16c) is a potent monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.3 μM. MAO-B-IN-12 shows a neuroprotective activity.

HY-151210

MAO-B-IN-17	Monoamine Oxidase	Neurological Disease
MAO-B-IN-17 is a selective monoamine oxidase B (MAO-B) inhibitor with the IC₅₀ value of 5.08 μM. MAO-B-IN-17 can be used in Parkinson’s disease research.

HY-146762

MAO-B-IN-7	Monoamine Oxidase Cholinesterase (ChE) Reactive Oxygen Species	Inflammation/Immunology Neurological Disease
MAO-B-IN-7 is a potent and blood-brain barrier permeable *MAO-B* and AChE inhibitor with IC₅₀s of 41 nM, 87 nM and 0.3 μM for human AChE, electric eel AChE and MAO-B, respectively. MAO-B-IN-7 can effectively alleviate oxidative stress and neuroinflammatory damage.

HY-151208

MAO-B-IN-16	Monoamine Oxidase	Neurological Disease
MAO-B-IN-16 is a selective monoamine oxidase B (MAO-B) inhibitor, with an IC₅₀ of 1.55 µM. MAO-B-IN-16 can be used in the study of central nervous disorders, such as parkinson's disease.

HY-151209

MAO-B-IN-15	Monoamine Oxidase	Neurological Disease
MAO-B-IN-15 is a selective *MAO-B* inhibitor (IC₅₀: 13.5 μM) that forms π-π interaction with Tyr 326 residue. MAO-B-IN-15 can be used in the research of Parkinson’s disease.

HY-132907

MAO-B-IN-2
Monoamine Oxidase Neurological Disease

MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC₅₀ values of 0.51 and 7.00 μM, respectively.

MAO-B-IN-2	Monoamine Oxidase	Neurological Disease
MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC₅₀ values of 0.51 and 7.00 μM, respectively.

HY-146347

MAO-B-IN-10	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-10 (compound 4f) is a potent, selective, BBB-penetrated *MAO-B* (monoamine oxidase-B) inhibitor, with IC₅₀ of 5.3 μM. MAO-B-IN-10 can inhibit (58.2%) and disaggregate (43.3%) self-mediated Aβ (amyloid β) aggregation. MAO-B-IN-10 can be use for Alzheimer’s disease research.

HY-146314

MAO-B-IN-9	Monoamine Oxidase Amyloid-β	Neurological Disease
MAO-B-IN-9 (compound 16) is a potent, selective, BBB-penetrated, irreversible and time-dependent *MAO-B* (monoamine oxidase B) inhibitor, with an IC₅₀ of 0.18 μM. MAO-B-IN-9 prevents Aβ_1-42-induced neuronal cell death. MAO-B-IN-9 shows neuroprotective effects, which may be the result of its Aβ_1-42 anti-aggregation effects.

HY-U00343

MAO-B-IN-1
Monoamine Oxidase Neurological Disease

MAO-B-IN-1 is an inhibitor of monoamine oxidase B, used for the research of neurological diseases.

MAO-B-IN-1	Monoamine Oxidase	Neurological Disease
MAO-B-IN-1 is an inhibitor of monoamine oxidase B, used for the research of neurological diseases.

HY-151596

MAO-A/5-HT2AR-IN-1	Monoamine Oxidase 5-HT Receptor	Neurological Disease
MAO-A/5-HT2AR-IN-1 (compound I14) is a potent *MAO-A* and 5-HT2AR dual inhibitor, with IC₅₀ values of 0.004 and 0.014 μM, respectively. MAO-A/5-HT2AR-IN-1 is a potential antidepressant agent.

HY-152109

*AChE/MAO-IN-1*	Cholinesterase (ChE) Monoamine Oxidase Amyloid-β	Neurological Disease
AChE/MAO-IN-1 (Compound D28) is a potent AChE, *MAO-A* and *MAO-B* inhibitor with IC₅₀s of 0.0248, 0.0409 and 0.1108 μM against human AChE, MAO-B and MAO-A, respectively.

HY-N0505

Rosiridin	Monoamine Oxidase	Neurological Disease
Rosiridin inhibits MAO A and MAO B with potential beneficial effect in depression and senile dementia. Rosiridin shows an inhibition of 83.8% against MAO B at 10 μM (pIC₅₀=5.38).

HY-152110

*AChE/MAO-IN-2*	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Dual AChE-MAO B-IN-5, indanone derivative, is a potent dual *AChE/MAO-B* inhibitior with IC₅₀ values of 0.0224, 0.0412, and 0.1116 μM for AChE, MAO-B and MAO-A, respectively. Dual AChE-MAO B-IN-5 has antioxidant activity and prevents β-amyloid plaque aggregation. Dual AChE-MAO B-IN-5 can be used for Alzheimer’s disease (AD) research.

HY-152111

*AChE/MAO-B-IN-3*	Cholinesterase (ChE) Monoamine Oxidase Amyloid-β	Neurological Disease
AChE/MAO-B-IN-3 (Compound D30) is a dual AChE and *MAO-B* inhibitor with IC₅₀s of 0.0257 μM and 0.0456 μM against human AChE and MAO-B, respectively. AChE/MAO-B-IN-3 can be used for the research of Alzheimer’s disease.

HY-145708

*Dual AChE-MAO* B-IN-2**	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Dual AChE-MAO B-IN-2 is a potent AChE and MAO B dual inhibitor with IC₅₀s of 0.12 µM and 0.01 µM for b>AChE and MAO B, respectively. Dual AChE-MAO B-IN-2 has the potential for the research of Alzheimer’s disease.

HY-152114

*AChE/BChE/MAO-B-IN-4*	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
AChE/BChE/MAO-B-IN-4, an indan-1-one derivative, is a potent *MAO-B* inhibitor with an IC₅₀ of 0.0393 μM for human MAO-B. AChE/BChE/MAO-B-IN-4 is a potent AChE and BChE enzyme inhibitor, with IC₅₀s of 0.0458 μM and 0.075 μM for human AChE and BChE enzyme, respectively. AChE/BChE/MAO-B-IN-4 shows significant antioxidant activity and prevent β-amyloid plaque aggregation. AChE/BChE/MAO-B-IN-4 has the potential for Alzheimer's disease (AD) research.

HY-145845

*HDAC1/MAO-B-IN-1*	HDAC Monoamine Oxidase	Neurological Disease
HDAC1/MAO-B-IN-1 is a potent, selective and cross the blood-brain barrier *HDAC1/MAO-B* inhibitor with IC₅₀ values of 21.4 nM and 99.0 nM for HDAC1 and MAO-B, respectively. HDAC1/MAO-B-IN-1 has the potential for the research of Alzheimer’s disease.

HY-152113

*AChE/BChE/MAO-B-IN-3*	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
AChE/BChE/MAO-B-IN-3, an indan-1-one derivative, is a potent *MAO-B* inhibitor with an IC₅₀ of 0.0359 μM for human MAO-B. AChE/BChE/MAO-B-IN-3 is a potent AChE and BChE enzyme inhibitor, with IC₅₀s of 0.0473 μM and 0.0782 μM for human AChE and BChE enzyme, respectively. AChE/BChE/MAO-B-IN-3 shows significant antioxidant activity and has the potential for Alzheimer's disease (AD) research.

HY-151885

*Dual AChE-MAO* B-IN-3**	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Dual AChE-MAO B-IN-3 (compound C10) is a potent dual *AChE/MAO-B* inhibitior, with IC₅₀ values of 0.58 and 0.41 μM, respectively. Dual AChE-MAO B-IN-3 is a dual-binding inhibitor bound to both the catalytic anionic site and peripheral anionic site of AChE. Dual AChE-MAO B-IN-3 can be used for Alzheimer’s disease (AD) research.

HY-152112

*AChE/BChE/MAO-B-IN-2*	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
AChE/BChE/MAO-B-IN-2 is a potent AChE, BChE, and *MAO-B* enzymes inhibitor with IC₅₀ values of 48.2 nM, 83.9 nM, and 31.2 nM, respectively. AChE/BChE/MAO-B-IN-2 has significant antioxidant activity, and can be used for Parkinson’s disease research.

HY-145695

*Dual AChE-MAO* B-IN-1**	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Dual AChE-MAO B-IN-1 (compound 15) is an orally bioavailable CNS-permeant potent inhibitor of both human AChE (IC₅₀=550 nM) and MAO B (IC₅₀=8.2 nM). Dual AChE-MAO B-IN-1 behaves as a safe and metabolically stable neuroprotective agent, devoid of cytochrome liability.

HY-146312

*AChE/BChE/MAO-B-IN-1*	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BChE/MAO-B-IN-1 (Compound 10) is a reversible and non-time-dependent AChE, BChE and *MAO-B* inhibitor with IC₅₀ values of 7.31, 0.56 and 26.1 μM for hAChE, hBChE and hMAO-B, respectively. AChE/BChE/MAO-B-IN-1 can cross the BBB and shows neuroprotective effects without cytotoxicity.

HY-146677

*5-HT6R/MAO-B modulator 1*	5-HT Receptor Monoamine Oxidase	Neurological Disease
5-HT6R/MAO-B modulator 1 (compound 48) is an antagonist of 5-HT₆R at Gs signaling and an irreversible *MAO-B* inhibitor. 5-HT6R/MAO-B modulator 1 exhibits glioprotective properties. 5-HT6R/MAO-B modulator 1 can reverse Scopolamine-induced memory deficits.

HY-151562

*AChE/BuChE/MAO-B-IN-1*	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE/BuChE/MAO-B-IN-1 (compound 19) is an inhibitor of human acetyl- (hAChE), butyrylcholinesterase (hBuChE) and monoamine oxidase-B (hMAO-B) with IC₅₀s of 4.8 μM, 13.7 μM, and 1.11 μM, respectively. AChE/BuChE/MAO-B-IN-1 also exhibits high affinity to both the σ₁ and σ₂ receptors with K_i values of 42.8 nM (human σ₁ receptor) and 191 nM (rat σ₂ receptor), respectively. AChE/BuChE/MAO-B-IN-1 can be used for Alzheimer’s disease research.

HY-Y0882

Hydroxyamine hydrochloride	Monoamine Oxidase	Cardiovascular Disease
Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis.

HY-10400

Ladostigil hemitartrate TV-3326 hemitartrate	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for *MAO-B* and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease.

HY-W193398

N-2-Cyclohexylethyl-N-methylamine	Monoamine Oxidase	Cardiovascular Disease
N-2-Cyclohexylethyl-N-methylamine is an amine from A.ridigula Benth for a reduction of monoamine oxidase (MAO) activity.

HY-19333

OG-L002	Histone Demethylase Monoamine Oxidase HSV	Infection
OG-L002 is a potent and highly selective LSD1 inhibitor with an IC₅₀ of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC₅₀s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes.

HY-W015490

1,4-Naphthoquinone	Monoamine Oxidase	Cancer
1,4-Naphthoquinone is a potential pharmacophore for inhibition of both MAO (monoamine oxidase) and DNA topoisomerase activities, this latter associated with antitumor activity.

HY-10399

Ladostigil TV-3326	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for *MAO-B* and AChE, respectively. Ladostigil exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease.

HY-10399A

Ladostigil hydrochloride TV-3326 hydrochloride	Monoamine Oxidase Cholinesterase (ChE)	Neurological Disease
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for *MAO-B* and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease.

HY-17447SA

Tranylcypromine-d5 hydrochloride SKF 385-d₅ (hydrochloride)	Monoamine Oxidase Histone Demethylase	Neurological Disease
Tranylcypromine-d₅ (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis[1][2].

HY-N9329

Glicoricone	Monoamine Oxidase Estrogen Receptor/ERR	Metabolic Disease
Glicoricone, a phenolic compound, is isolated from a species of licorice. Glicoricone is an inhibitor of monoamine oxidase (MAO), with an IC₅₀ of 140 μM. Glicoricone binds to estrogen receptor (ER) and shows estrogen antagonist activity.

HY-W008566

Norharmane Norharman; β-Carboline	Monoamine Oxidase Endogenous Metabolite	Cancer Infection Neurological Disease
Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible monoamine oxidase inhibitor, with IC₅₀ values of 6.5 and 4.7 μM for *MAO-A* and *MAO-B, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana* seedlings.

HY-101392

Harmane	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Cancer Neurological Disease
Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for *human MAO* A/B**, respectively). Harmane exhibits comutagenic effect.

HY-16677A

Mofegiline hydrochloride MDL72974A	Monoamine Oxidase	Neurological Disease
Mofegiline hydrochloride (MDL72974A) is an orally active and selective enzyme-activated irreversible inhibitor of *MAO-B, with marked selectivity on the MAO-B* over *MAO-A* with IC₅₀s of 3.6 nM (MAO-B) and 680 nM (MAO-A), respectively. Mofegiline hydrochloride is also an inhibitor of semicarbazide-sensitive amine oxidase (SSAO).

HY-13779

J-147	Monoamine Oxidase Dopamine Transporter	Neurological Disease
J-147 is an exceptionally potent, orally active, neuroprotective agent for cognitive enhancement. J-147 can readily pass the blood brain barrier (BBB). J-147 can inhibit monoamine oxidase B (MAO B) and the dopamine transporter with EC₅₀ values of 1.88 μM and 0.649 μM, respectively. J-147 has potential for the treatment of Alzheimer’s disease (AD).

HY-13339

Brofaromine
CGP 11305A
Monoamine Oxidase Neurological Disease

Brofaromine (CGP 11305A) is a monoamine oxidase (MAO) inhibitor with IC₅₀ of 0.2 μM for MAO-A.

HY-A0091

Pargyline hydrochloride	Monoamine Oxidase	Cancer Cardiovascular Disease
Pargyline hydrochloride is an irreversible monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for *MAO-A* and *MAO-B*, respectively. Pargyline hydrochloride has antihypertensive and anticancer activities.

HY-A0091A

Pargyline	Monoamine Oxidase	Cancer Cardiovascular Disease
Pargyline is an irreversible monoamine oxidase (MAO) inhibitor with K_is of 13 μM and 0.5 μM for *MAO-A* and *MAO-B*, respectively. Pargyline has antihypertensive and anticancer activities.

HY-N0453

Hypericin	Apoptosis Influenza Virus Antibiotic Monoamine Oxidase PKC Cytochrome P450 Dopamine β-hydroxylase Reverse Transcriptase Telomerase	Cancer Infection Neurological Disease
Hypericin is a naturally occurring substance found in Hyperlcurn perforatum L. Hypericin is an inhibitor of PKC (protein kinase C), *MAO* (monoaminoxidase), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450). Hypericin shows antitumor, antiviral, antidepressive activities, and can induce apoptosis.

HY-N0159

Paeonol	Monoamine Oxidase Autophagy	Neurological Disease Cancer
Paeonol is an active extraction from the root of Paeonia suffruticosa, Paeonol inhibits *MAO-A* and *MAO-B* with IC₅₀ of 54.6 μM and 42.5 μM, respectively.

HY-E70074

Monoamine oxidase	Monoamine Oxidase	Neurological Disease
Monoamine oxidase is an enzyme composed of different polypeptides. Monoamine oxidation catalyzes the oxidative deamination of various biological amines in brain and peripheral tissues by producing hydrogen peroxide. Monoamine oxidase plays an important role in maintaining the regulation of synaptic transmission, emotional behavior and other brain functions.

HY-151094

FTEAA	Monoamine Oxidase	Neurological Disease
FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC₅₀s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research.

HY-N0529

Rosmarinic acid Labiatenic acid	Monoamine Oxidase COMT Apoptosis Endogenous Metabolite	Cancer
Rosmarinic acid is a widespread phenolic ester compound in the plants. Rosmarinic acid inhibits *MAO-A, MAO-B* and COMT enzymes with IC₅₀s of 50.1, 184.6 and 26.7 μM, respectively.

HY-17447A

Tranylcypromine hydrochloride SKF 385 hydrochloride	Monoamine Oxidase	Neurological Disease
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase *(MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO* A and MAO B with IC₅₀s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression.

HY-B1083

Modaline sulfate
Monoamine Oxidase Neurological Disease

Modaline sulfate is a MAO inhibitor, used in the treatment of depression.
HY-139647

(+)-Cinchonaminone
Monoamine Oxidase Others

(+)-Cinchonaminone shows monoamine oxidase (MAO) inhibitory activity.

HY-D0004

Azure B Azure B chloride	Monoamine Oxidase	Neurological Disease
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC₅₀s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects.

HY-14605

Rasagiline mesylate (R)-AGN1135 mesylate; TVP1012 mesylate	Monoamine Oxidase Autophagy Apoptosis	Neurological Disease
Rasagiline (R-AGN1135) mesylate is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.

HY-14605A

Rasagiline (R)-AGN1135; TVP1012	Monoamine Oxidase	Neurological Disease
Rasagiline (R-AGN1135) is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.

HY-22385

Salsolidine
Monoamine Oxidase Neurological Disease

Salsolidine is a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A inhibitor.
HY-14260

RS 8359
Monoamine Oxidase Neurological Disease

RS 8359 is a selective and reversible MAO-A inhibitor, with antidepressant activity.

HY-14200

(S)-Rasagiline TVP1022; S-PAI	Monoamine Oxidase	Neurological Disease
(S)-Rasagiline (TVP1022) is the relatively inactive S-enantiomer form of Rasagiline. Rasagiline is a highly potent selective irreversible *MAO* inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.

HY-14200A

(S)-Rasagiline mesylate TVP1022 mesylate; S-PAI mesylate	Monoamine Oxidase	Neurological Disease
(S)-Rasagiline (TVP1022) mesylate is the relatively inactive S-enantiomer form of Rasagiline mesylate. Rasagiline mesylate is a highly potent selective irreversible *MAO* inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.

HY-B0884

Minaprine
Monoamine Oxidase Neurological Disease

Minaprine is a reversible inhibitor of MAO-A; weakly inhibit acetylcholinesterase; an antidepressant for treatment of depression.

HY-B0884A

Minaprine dihydrochloride	Monoamine Oxidase	Neurological Disease
Minaprine dihydrochloride is a reversible inhibitor of MAO-A; weakly inhibit acetylcholinesterase; an antidepressant for treatment of depression.

HY-22385A

Salsolidine hydrochloride	Monoamine Oxidase	Neurological Disease
Salsolidine hydrochloride, a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A (monoamine oxidase A) inhibitor.

HY-17447

Tranylcypromine
SKF 385
Monoamine Oxidase Endocrinology Cardiovascular Disease

Tranylcypromine (SKF 385) is a potent monoamine oxidase (MAO) inhibitor.

HY-144673

LSD1-IN-12	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-12 (compound 2) is a potent LSD1 inhibitor, with K_i values of 1.1 μM (LSD1), 61 μM (LSD2), 2.3 μM (MAO-A), and 3.5 μM (MAO-B), respectively.

HY-143438

2-PAT	Monoamine Oxidase	Neurological Disease
2-PAT, an analogue of Rasagiline and Selegiline, a reversible *MAO-A* inhibitor with an IC₅₀ of 0.721 µM. 2-PAT is an inactivator of MAO-B with an IC₅₀ of 14.6 µM. 2-PAT has the potential for Parkinson’s disease and depression research.

HY-N1638

1-Methyl-2-undecyl-4(1H)-quinolone	Monoamine Oxidase	Neurological Disease
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of *MAO-B* activity with the IC₅₀ and K_i values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS.

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride (1S,2R)-SKF 385-d₅ hydrochloride	Monoamine Oxidase	Neurological Disease
(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

HY-100178

CX-157
Monoamine Oxidase Neurological Disease

CX-157 is a reversible inhibitor of monoamine oxidase-A (MAO-A) with an EC₅₀ of 19.3 ng/mL.

HY-100588

VU0364770	mGluR	Neurological Disease
VU0364770 is a selective and potent positive allosteric modulator (PAM) of mGlu4. VU0346770 exhibits EC₅₀s of 290 nM and 1.1 μM at rat mGlu4 and human mGlu4 receptor, respectively. VU0364770 exhibits antagonist activity at mGlu5 with a potency of 17.9 μM and PAM activity at mGlu6 with a potency of 6.8 μM. VU0364770 also possesses activity at MAO with K_i values of 8.5 and 0.72 μM for human MAO-A and human MAO-B, respectively.

HY-100588A

VU0364770 hydrochloride	mGluR	Neurological Disease
VU0364770 hydrochloride is a selective and potent positive allosteric modulator (PAM) of mGlu4. VU0346770 hydrochloride exhibits EC₅₀s of 290 nM and 1.1 μM at rat mGlu4 and human mGlu4 receptor, respectively. VU0364770 hydrochloride exhibits antagonist activity at mGlu5 with a potency of 17.9 μM and PAM activity at mGlu6 with a potency of 6.8 μM. VU0364770 hydrochloride also possesses activity at MAO with K_i values of 8.5 and 0.72 μM for human MAO-A and human MAO-B, respectively.

HY-14197A

Clorgyline hydrochloride	Monoamine Oxidase	Metabolic Disease
Clorgyline hydrochloride is an irreversible and selective inhibitor of monoamine oxidase A (MAO-A) that is used in scientific research; structurally related to Pargyline.

HY-119885A

(±)-Amiflamine
FLA 336
Monoamine Oxidase Neurological Disease

(±)-Amiflamine (FLA 336) is a potent monoamine oxidase-A (MAO-A) inhibitor with a pIC₅₀ of 5.57.
HY-148145

Mebanazine
Monoamine Oxidase Neurological Disease

Mebanazine is a potent monoamine oxidase (MAO) inhibitor. Mebanazine can be used in research of depression.
HY-148146

Phenoxypropazine
Monoamine Oxidase Neurological Disease

Phenoxypropazine is a potent monoamine oxidase (MAO) inhibitor. Phenoxypropazine can be used in research of depression.

HY-144824

Monoamine oxidase/Aromatase-IN-1	Cytochrome P450 Monoamine Oxidase	Cancer Neurological Disease
Monoamine oxidase/Aromatase-IN-1 (compound 2q) is a highly potent monoamine oxidase (MAO) and aromatase dual inhibitor with IC₅₀s of 39 nM and 31 nM for MAO-B and aromatase, respectively. Monoamine oxidase/Aromatase-IN-1 can be used for researching neurological disorder and breast cancer.

HY-110130

RN-1 dihydrochloride	Histone Demethylase	Cancer Cardiovascular Disease
RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC₅₀ values of 0.51 μM and 2.785 μM respectively.

HY-B1558A

Bifemelane hydrochloride MCI-2016	Monoamine Oxidase	Neurological Disease
Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a K_i of 4.20 μM. Bifemelane hydrochloride also inhibits *MAO-B* noncompetitively with a K_i of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease.

HY-W010130

7-Hydroxy-3,4-dihydro-2(1H)-quinolinone 3,4-Dihydro-7-hydroxy-2(1H)-quinolinone	Monoamine Oxidase	Neurological Disease
7-Hydroxy-3,4-dihydro-2(1H)-quinolinone (3,4-Dihydro-7-hydroxy-2(1H)-quinolinone) is a weak *MAO-A* inhibitor, with an IC₅₀ of 183 μM, and has no effect on MAO-B.

HY-N0918

Desmethoxyyangonin Demethoxyyangonin; 5,6-Dehydrokavain	Monoamine Oxidase	Others
Desmethoxyyangonin is one of the six major kavalactones found in the Piper methysticum (kava) plant; reversible inhibitor of MAO-B.

HY-B0886A

Iproniazid	Monoamine Oxidase	Neurological Disease
Iproniazid is a non-selective, irreversible monoamine oxidase (MAO) inhibitor of the hydrazine class. Iproniazid has antidepressive activity.

HY-107811

Harmol
Monoamine Oxidase Neurological Disease

Harmol categorized as a β-carboline alkaloid. Harmol is a potent MAO inhibitor used as an analytical reference standard.

HY-B0886

Iproniazid phosphate	Monoamine Oxidase	Neurological Disease
Iproniazid phosphate is a non-selective, irreversible monoamine oxidase (MAO) inhibitor of the hydrazine class. Iproniazid phosphate has antidepressive activity.

HY-148159

Safrazine	Monoamine Oxidase	Neurological Disease
Safrazine is an irreversible, non-specific and orally active monoamine oxidase (MAO) inhibitor. Safrazine can be used for the research of depression.

HY-148158

Pivalylbenzhydrazine Pivhydrazine	Monoamine Oxidase	Inflammation/Immunology Neurological Disease
Pivalylbenzhydrazine (Pivhydrazine) is a potent monoamine oxidase (MAO) inhibitor. Pivalylbenzhydrazine decreases cartilage growth in normal rats. Pivalylbenzhydrazine can be used in research of depression.

HY-141682

THK-5470	Monoamine Oxidase	Neurological Disease
THK-5470, a monoamine oxidase-B (MAO-B) imaging probe, could be used for neurological diseases study. THK-5470 shows remarkably high binding affinity against MAO-B with an IC50 value of 4.2 nM, low binding affinity against tau with an IC50 value of 4462 nM. THK-5470 has high selective binding property and high affinity (from patent EP2019-846498).

HY-112623

Vafidemstat ORY-2001	Histone Demethylase Monoamine Oxidase	Neurological Disease
Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.

HY-100679A

Pirlindole mesylate	Monoamine Oxidase Enterovirus	Infection Endocrinology
Pirlindole mesylate is a selective and reversible *MAO-A* inhibitor. Pirlindole is also an inhibitor of enterovirus-D68 and coxsackievirus B3 (CV-B3) .

HY-144758

LSD1-IN-17	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-17 (compound 5b) is a potent LSD1 inhibitor. LSD1-IN-17 can inhibit LSD1-CoREST, *MAO-A* and *MAO-B, with IC₅₀* values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 17.2 μM.

HY-144756

LSD1-IN-15	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-15 (compound 1b) is a potent LSD1 inhibitor. LSD1-IN-15 can inhibit LSD1-CoREST, *MAO-A* and *MAO-B, with IC₅₀* values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 9.9 μM.

HY-14202

Lazabemide hydrochloride Ro 19-6327 hydrochloride	Monoamine Oxidase	Neurological Disease
Lazabemide hydrochloride (Ro 19-6327 hydrochloride) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC₅₀=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide inhibits monoamine uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease.

HY-14201

Lazabemide Ro 19-6327	Monoamine Oxidase	Neurological Disease
Lazabemide (Ro 19-6327) is a selective, reversible inhibitor of monoamine oxidase B (MAO-B) (IC₅₀=0.03 μM) but less active for MAO-A (IC₅₀>100 μM). Lazabemide inhibits monoamine uptake at high concentrations, the IC₅₀ values are 86 μM, 123 μM and >500 μM for noradrenalin, serotonin and dopamine uptake, respectively. Lazabemide can be used for the research of parkinson and alzheimer′s disease.

HY-144757

LSD1-IN-16	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-16 (compound 4b) is a potent LSD1 inhibitor. LSD1-IN-16 can inhibit LSD1-CoREST, *MAO-A* and *MAO-B, with IC₅₀* values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 15.2 μM.

HY-100679

Pirlindole	Monoamine Oxidase Enterovirus	Infection Neurological Disease
Pirlindole is a selective and reversible *MAO-A* inhibitor. Pirlindole is also an inhibitor of enterovirus-D68 and coxsackievirus B3 (CV-B3).

HY-15386

Cimoxatone MD 780515	Monoamine Oxidase	Metabolic Disease
Cimoxatone (MD 780515) is a reversible, selectively and orally active type A monoamine oxidase (MAO-A) inhibitor. Cimoxatone enhances the anorectic action of Serotonin (HY-B1473A).

HY-22385B

(S)-Salsolidine	Monoamine Oxidase Endogenous Metabolite	Neurological Disease
(S)-Salsolidine is a weak monoamine oxidase (MAO) inhibitor (K_i=63 μM). The R enantiomer of Salsolidine is more potent than the S form (K_i=26 μM).

HY-14605BS

Rasagiline-13C3 mesylate racemic AGN1135-¹³C₃; TVP1012-¹³C₃ racemic	Monoamine Oxidase	Neurological Disease
Rasagiline-¹³C₃ (mesylate racemic) is a ¹³C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1].

HY-141681

THK-5475	Monoamine Oxidase	Neurological Disease
THK-5475 is a precursor of THK-5470, a monoamine oxidase-B(MAO-B) imaging probe, could be used for neurological diseases study (from patent EP2019-846498).

HY-Y0882S1

Hydroxylamine-d3 hydrochloride	Monoamine Oxidase	Cardiovascular Disease
Hydroxylamine-d₃ (hydrochloride) is the deuterium labeled Hydroxyamine hydrochloride[1]. Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis[2].

HY-N9540

Methyl citrate	Monoamine Oxidase	Neurological Disease
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino.

HY-108048

Desoxypeganine Deoxypeganine; Deoxyvasicine	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Desoxypeganine (Deoxypeganine), an alkaloid, is a potent and orally active cholinesterase (BChE and AChE) and selective *MAO-A* inhibitor, with IC₅₀ values of 2, 17, and 2 μM, respectively. Desoxypeganine can be used for alcohol abuse research.

HY-70057

Safinamide FCE 26743; EMD 1195686	Monoamine Oxidase	Neurological Disease
Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 µM) over MAO-A (IC₅₀=580 µM). Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8 µM) than at resting (IC₅₀=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al.

HY-B0534

Moclobemide Ro111163	Monoamine Oxidase	Neurological Disease
Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC₅₀ of 6.061 μM for hMAO-A.Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

HY-70057A

Safinamide mesylate FCE 26743 mesylate; EMD 1195686 mesylate	Monoamine Oxidase	Neurological Disease Cardiovascular Disease
Safinamide (FCE 26743; EMD 1195686) mesylate is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.098 µM) over MAO-A (IC₅₀=580 nM). Safinamide mesylate also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC₅₀=8 µM) than at resting (IC₅₀=262 µM) potentials. Safinamide mesylate has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke et.al.

HY-120017

Befloxatone MD-370503	Monoamine Oxidase	Neurological Disease
Befloxatone (MD-370503) is an orally active, selective and reversible inhibitor of Monoamine Oxidase A (MAO-A) (IC₅₀=4 nM). Befloxatone increases the tissue level of monoamine, striatal dopamine and cortical norepinephrine. Befloxatone has antidepressant potential.

HY-N2510

Myristicin Myristicine	5-HT Receptor	Neurological Disease
Myristicine act as a serotonin receptor antagonist, a weak monamine oxidase (MAO) inhibitor. Myristicine is the main component of nutmeg essential oil from Myristica fragrans Houtt. Myristicine abuse produce hallucinogenic effects, organ damage, deliriumand others.

HY-120419

PF9601N	Monoamine Oxidase	Neurological Disease
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity.

HY-101392S1

Harmane-d2	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Cancer Neurological Disease
Harmane-d₂ is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-14280A

Entacapone sodium salt	COMT	Neurological Disease
Entacapone sodium salt is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone sodium salt inhibits COMT from rat brain, erythrocytes and liver with IC₅₀ values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone sodium salt is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC₅₀s>50 µM). Entacapone sodium salt can be used for the research of Parkinson's disease. Entacapone sodium salt serves as as a inhibit of FTO demethylation with an IC₅₀ of 3.5 μM, can be used for the research of metabolic disorders.

HY-101392S

Harmane-d1	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Cancer Neurological Disease
Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-70057S1

Safinamide-d4-1 FCE 26743-d₄-1; EMD 1195686-d₄-1	Monoamine Oxidase	Neurological Disease
Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

HY-14280

Entacapone	COMT	Neurological Disease
Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC₅₀ values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC₅₀s>50 µM). Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibitor of FTO demethylation with an IC₅₀ of 3.5 μM, can be used for the research of metabolic disorders.

HY-17447G

Tranylcypromine SKF 385	Monoamine Oxidase	Endocrinology Cardiovascular Disease
Tranylcypromine (SKF 385) (GMP) is Tranylcypromine (HY-17447) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tranylcypromine (SKF 385) is a potent monoamine oxidase (MAO) inhibitor.

HY-14280S

Entacapone-d10	COMT	Neurological Disease
Entacapone-d₁₀ is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

HY-W015490S

1,4-Naphthoquinone-d6	Monoamine Oxidase	Cancer
1,4-Naphthoquinone-d₆ is the deuterium labeled 1,4-Naphthoquinone[1]. 1,4-Naphthoquinone is a potential pharmacophore for inhibition of both MAO (monoamine oxidase) and DNA topoisomerase activities, this latter associated with antitumor activity[2].

HY-B0534S1

Moclobemide-d4 Ro111163-d₄	Monoamine Oxidase	Neurological Disease
Moclobemide-d₄ is deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A[1].Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

HY-14280S2

(E)-Entacapone-d10	COMT	Neurological Disease
(E)-Entacapone-d₁₀ is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

HY-17447B

(1S,2R)-Tranylcypromine hydrochloride (1S,2R)-SKF 385 hydrochloride	Monoamine Oxidase Histone Demethylase	Neurological Disease
(1S,2R)-Tranylcypromine ((1S,2R)-SKF 385) hydrochloride is a potent antidepressant agent. (1S,2R)-Tranylcypromine hydrochloride can inhibits *MAO* and LSD1.

HY-135265

Moclobemide N-Oxide Ro 12-5637	Monoamine Oxidase	Neurological Disease
Moclobemide N-Oxide (Ro 12-5637) is N-oxide metabolite of Moclobemide. Moclobemide N-Oxide retains certain *MAO-A* (monoamine oxidase) inhibitory activity, but is generally present in low concentrations. Moclobemide N-Oxide can be detected by UV absorption at 240 nm.

HY-100027A

Ro 41-1049 hydrochloride	Monoamine Oxidase	Neurological Disease
Ro 41-1049 hydrochloride is a reversible and selective inhibitor of monoamine oxidase-A (MAO-A). An homogeneous population of high affinity binding sites for [³H]Ro 41-1049 is found in membrane preparations from human frontal cortex and placenta (K_d values of 16.5 and 64.4 nM, respectively).

HY-B1496

Tranylcypromine hemisulfate SKF 385 hemisulfate	Monoamine Oxidase Histone Demethylase	Neurological Disease
Tranylcypromine (SKF 385) hemisulfate is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hemisulfate is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Tranylcypromine has antidepressant effects.

HY-N7204

4-Hydroxyderricin	Monoamine Oxidase Dopamine β-hydroxylase	Neurological Disease
4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is a potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an IC₅₀ of 3.43 μM. 4-Hydroxyderricin also mildly inhibits DBH (dopamine β-hydroxylase) activity. 4-Hydroxyderricin has antidepressant activity.

HY-143238

FY-56	Histone Demethylase	Cancer
FY-56 is a highly potent and selective LSD1/KDM1A inhibitor (IC₅₀=42 nM) and exhibits high selectivity over MAO-A/B. FY-56 induces differentiation of MOLM-13 and MV4-11 cell and has the potential for AML research.

HY-N1636

1-Methyl-2-nonyl-4(1H)-quinolone	Monoamine Oxidase	Neurological Disease
1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective *MAO-B* (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC₅₀ of 12.1 μM.

HY-129388A

Pulrodemstat CC-90011; LSD1-IN-7	Histone Demethylase	Cancer
Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity.

HY-Y0265

Isatin Indoline-2,3-dione	Monoamine Oxidase Apoptosis	Cancer Neurological Disease Cardiovascular Disease
Isatin (Indoline-2,3-dione) is a potent inhibitor of monoamine oxidase (MAO) with an IC₅₀ of 3 μM. Also binds to central benzodiazepine receptors (IC₅₀ against clonazepam, 123 μM). Also acts as an antagonist of both atrial natriuretic peptide stimulated and nitric oxide-stimulated guanylate cyclase activity. Shows effect on the serotonergic system.

HY-103164

(E)-8-(3-Chlorostyryl)caffeine	Adenosine Receptor Monoamine Oxidase	Neurological Disease
(E)-8-(3-Chlorostyryl)caffeine is a selective adenosine A_2A receptor antagonist. (E)-8-(3-Chlorostyryl)caffeine inhibits monoamine oxidase B (MAO-B) with a K_i value of 70 nM by a pathway that is independent of its actions on the A_2A receptor. (E)-8-(3-Chlorostyryl)caffeine has the potential for Parkinson's disease research.

HY-143245

Monoamine Oxidase B inhibitor 2	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 2 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 1.33 nM. Monoamine Oxidase B inhibitor 2 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 2 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study.

HY-143244

Monoamine Oxidase B inhibitor 1	Monoamine Oxidase	Neurological Disease
Monoamine Oxidase B inhibitor 1 is a potent, reversible, orally active and selective monoamine oxidase B (MAO-B) inhibitor with an IC₅₀ of 0.02 nM. Monoamine Oxidase B inhibitor 1 has antioxidant and anti-neuroinflammatory activities. Monoamine Oxidase B inhibitor 1 can across the blood-brain barrier (BBB), and can be used for Parkinson’s disease study.

HY-W001601

Budipine	iGluR	Neurological Disease
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease.

HY-151388

hMAO-B/MB-COMT-IN-1	Monoamine Oxidase COMT	Neurological Disease
hMAO-B/MB-COMT-IN-1 is a dual *MAO-B/MB-COMT* inhibitor (IC₅₀s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD).

HY-129388B

Pulrodemstat benzenesulfonate CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate	Histone Demethylase	Cancer
CC-90011 benzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. CC-90011 benzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity.

HY-B1359

Methylene blue trihydrate C.I. Basic Blue 9 trihydrate	Guanylate Cyclase Monoamine Oxidase NO Synthase Parasite	Cancer Infection Neurological Disease
Methylene blue trihydrate (C.I. Basic Blue 9 trihydrate) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue trihydrate is a vasopressor and is often used as a dye in several medical procedures. Methylene blue trihydrate has antinociception, antimalarial, antidepressant and anxiolytic activity effects. Methylene Blue trihydrate has the potential for methemoglobinemias, neurodegenerative disorders and ifosfamide-induced encephalopathytreatment.

HY-145259

HDAC6-IN-3	HDAC Histone Demethylase	Cancer
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective *MAO-A* (IC₅₀=0.79 μM) and LSD1 inhibitor.

HY-143721

SSAO inhibitor-2	Monoamine Oxidase	Metabolic Disease Cardiovascular Disease Inflammation/Immunology
SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC₅₀s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc.

HY-151390

hMAO-B/MB-COMT-IN-2	Monoamine Oxidase COMT	Neurological Disease
hMAO-B/MB-COMT-IN-2 is a dual *MAO-B/MB-COMT* inhibitor (IC₅₀s: 4.27 μΜ for hMAO-B, 2.69 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-2 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-2 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD).

HY-129388

Pulrodemstat Methylbenzenesulfonate CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate	Histone Demethylase	Cancer
CC-90011 Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. CC-90011 Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 Methylbenzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity.

HY-151466

HIF-1α-IN-5	HIF/HIF Prolyl-Hydroxylase Monoamine Oxidase	Cancer
HIF-1α-IN-5 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-5 also inhibits MAO-A activity. HIF-1α-IN-5 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-5 can be used in the research of cancer.

HY-14536

Methylene Blue Basic Blue 9; CI-52015; Methylthioninium chloride	Guanylate Cyclase Monoamine Oxidase NO Synthase Microtubule/Tubulin	Cancer Infection Neurological Disease
Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.

HY-D0958

Methylene blue hydrate Basic Blue 9 hydrate; CI-52015 hydrate; Methylthioninium chloride hydrate	Guanylate Cyclase Monoamine Oxidase NO Synthase Microtubule/Tubulin	Cancer Infection Inflammation/Immunology
Methylene blue (Basic Blue 9) hydrate is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue hydrate through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue hydrate is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue hydrate is a Tau aggregation inhibitor. Methylene blue hydrate reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.

HY-115973

AChE-IN-11	Cholinesterase (ChE)	Neurological Disease
AChE-IN-11 (compound 5C) is a good multifunctional agent (AChE IC₅₀ = 7.9 μM, MAO-B IC₅₀ = 9.9 μM, BACE1 IC₅₀ = 8.3 μM). AChE-IN-11 displays a mixed-type AChE inhibition, which can bind to the CAS and PAS of AChE. AChE-IN-11 also exhibits good antioxidant activity (ORAC = 2.5 eq) and neuroprotective effects. AChE-IN-11 is a selective metal ions chelator. AChE-IN-11 has the potential for the research of AD.

HY-150563

Neuroinflammatory-IN-2	Monoamine Oxidase Amyloid-β	Inflammation/Immunology Neurological Disease
Neuroinflammatory-IN-2 is a potent anti-neuroinflammatory agent with an IC₅₀ value of 10.30 μM for *MAO-B, and 96.33% inhibition of Aβ_1-42* aggregation at 25 μM. Neuroinflammatory-IN-2 has neuroprotective activity in H₂O₂-induced PC-12 cell injury. Neuroinflammatory-IN-2 also has biometal chelating abilities, antioxidant activity, anti-neuroinflammatory activity and appropriate BBB permeability. Neuroinflammatory-IN-2 can be used for researching Alzheimer’s disease.

Cat. No.	Product Name	Type

HY-D0004

Azure B Azure B chloride	Dyes
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC₅₀s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects.

HY-14536

Methylene Blue

Basic Blue 9; CI-52015; Methylthioninium chloride

Chromogenic Assays

Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.

Cat. No.	Product Name	Type

HY-E70074

Monoamine oxidase	Enzyme
Monoamine oxidase is an enzyme composed of different polypeptides. Monoamine oxidation catalyzes the oxidative deamination of various biological amines in brain and peripheral tissues by producing hydrogen peroxide. Monoamine oxidase plays an important role in maintaining the regulation of synaptic transmission, emotional behavior and other brain functions.

Cat. No.	Product Name	Target	Category

HY-N0505

Rosiridin	Monoamine Oxidase	Terpenoids Other Monoterpenes Source classification Plants Crassulaceae Rhodiola rosea Linn.
Rosiridin inhibits MAO A and MAO B with potential beneficial effect in depression and senile dementia. Rosiridin shows an inhibition of 83.8% against MAO B at 10 μM (pIC₅₀=5.38).

HY-N9329

Glicoricone	Monoamine Oxidase Estrogen Receptor/ERR	Flavonoids Isoflavones Phenols Polyphenols Classification of Application Fields Disease Research Fields Metabolic Disease Source classification Plants Leguminosae Glycyrrhiza uralensis Fisch.
Glicoricone, a phenolic compound, is isolated from a species of licorice. Glicoricone is an inhibitor of monoamine oxidase (MAO), with an IC₅₀ of 140 μM. Glicoricone binds to estrogen receptor (ER) and shows estrogen antagonist activity.

HY-W008566

Norharmane Norharman; β-Carboline	Monoamine Oxidase Endogenous Metabolite	Alkaloids Pyridine Alkaloids Indole Alkaloids Source classification Microorganisms Endogenous metabolite
Norharmane (Norharman), a β-carboline alkaloid, is a potent and reversible monoamine oxidase inhibitor, with IC₅₀ values of 6.5 and 4.7 μM for *MAO-A* and *MAO-B, respectively. Norharmane causes antidepressant responses. Norharmane is also a prospective anti-cancer photosensitizer. Norharmane alters polar auxin transport (PAT) by inhibiting PIN2, PIN3 and PIN7 transport proteins, thus causing a significant inhibitory effect on the growth of Arabidopsis thaliana* seedlings.

HY-101392

Harmane	Imidazoline Receptor Monoamine Oxidase Adrenergic Receptor	Alkaloids Pyridine Alkaloids Indole Alkaloids Source classification Plants other families
Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC₅₀=30 nM) over α2-adrenoceptor (IC₅₀=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC₅₀s=0.5 and 5 μM for *human MAO* A/B**, respectively). Harmane exhibits comutagenic effect.

HY-N0453

Hypericin	Apoptosis Influenza Virus Antibiotic Monoamine Oxidase PKC Cytochrome P450 Dopamine β-hydroxylase Reverse Transcriptase Telomerase	Phenols Polyphenols Natural Products Classification of Application Fields Disease Research Fields Cancer Source classification Plants Guttiferae Hyperlcurn perforatum L.
Hypericin is a naturally occurring substance found in Hyperlcurn perforatum L. Hypericin is an inhibitor of PKC (protein kinase C), *MAO* (monoaminoxidase), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450). Hypericin shows antitumor, antiviral, antidepressive activities, and can induce apoptosis.

HY-N0159

Paeonol	Monoamine Oxidase Autophagy	Monophenols Phenols Neurological Disease Disease Research Fields Cancer Classification of Application Fields Source classification Plants Paeoniaceae Paeonia suffruticosa Andr.
Paeonol is an active extraction from the root of Paeonia suffruticosa, Paeonol inhibits *MAO-A* and *MAO-B* with IC₅₀ of 54.6 μM and 42.5 μM, respectively.

HY-N0529

Rosmarinic acid Labiatenic acid	Monoamine Oxidase COMT Apoptosis Endogenous Metabolite	Other Phenylpropanoids Phenylpropanoids Disease Research Fields Cancer Classification of Application Fields Source classification Plants Labiatae Brachyclados megalanthus Speg. Endogenous metabolite
Rosmarinic acid is a widespread phenolic ester compound in the plants. Rosmarinic acid inhibits *MAO-A, MAO-B* and COMT enzymes with IC₅₀s of 50.1, 184.6 and 26.7 μM, respectively.

HY-22385

Salsolidine	Monoamine Oxidase	Alkaloids Isoquinoline Alkaloids Source classification Animals
Salsolidine is a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A inhibitor.

HY-22385A

Salsolidine hydrochloride	Monoamine Oxidase	Alkaloids Isoquinoline Alkaloids Source classification Plants other families
Salsolidine hydrochloride, a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A (monoamine oxidase A) inhibitor.

HY-N1638

1-Methyl-2-undecyl-4(1H)-quinolone	Monoamine Oxidase	Alkaloids Quinoline Alkaloids Source classification Plants Rutaceae Evodia rutaecarpa (Juss.) Benth.
1-Methyl-2-undecyl-4(1H)-quinolone is a potent, irreversible and selective inhibitor of type B monoamine oxidase (MAO-B). 1-Methyl-2-undecyl-4(1H)-quinolone shows a selective inhibition of *MAO-B* activity with the IC₅₀ and K_i values of 15.3 μM and 9.91 μM, respectively, but did not inhibit type A MAO (MAO-A) activity. Methyl-2-undecyl-4(1H)-quinolone, as a quinolone alkaloid, is isolated from fresh leaves and fruits of Evodia rutaecarpa HOOK. f. et THOMS.

HY-N0918

Desmethoxyyangonin Demethoxyyangonin; 5,6-Dehydrokavain	Monoamine Oxidase	Phenylpropanoids Other Phenylpropanoids Classification of Application Fields Disease Research Fields Other Diseases Source classification Plants other families
Desmethoxyyangonin is one of the six major kavalactones found in the Piper methysticum (kava) plant; reversible inhibitor of MAO-B.

HY-107811

Harmol	Monoamine Oxidase	Indole Alkaloids Alkaloids Monophenols Phenols Pyridine Alkaloids Zygophyllaceae Peganum harmala Linn. Endogenous metabolite Plants Source classification Neurological Disease Disease Research Fields Classification of Application Fields
Harmol categorized as a β-carboline alkaloid. Harmol is a potent *MAO* inhibitor used as an analytical reference standard.

HY-22385B

(S)-Salsolidine	Monoamine Oxidase Endogenous Metabolite	Alkaloids Isoquinoline Alkaloids Source classification Plants Chenopodiaceae Salsola
(S)-Salsolidine is a weak monoamine oxidase (MAO) inhibitor (K_i=63 μM). The R enantiomer of Salsolidine is more potent than the S form (K_i=26 μM).

HY-N9540

Methyl citrate	Monoamine Oxidase	Ketones, Aldehydes, Acids Source classification Plants Cactaceae Opuntia ficus-indica (L.) Mill.
Methyl citrate is a Monoamine oxidase B (MAO-B) inhibitor (IC₅₀=0.23 mM). Methyl citrate is isolated from the fruits of Opuntia ficus-indica var. saboten Makino.

HY-108048

Desoxypeganine Deoxypeganine; Deoxyvasicine	Cholinesterase (ChE) Monoamine Oxidase	Structural Classification Alkaloids Quinoline Alkaloids Source classification Plants Zygophyllaceae Peganum nigellastrum Bunge
Desoxypeganine (Deoxypeganine), an alkaloid, is a potent and orally active cholinesterase (BChE and AChE) and selective *MAO-A* inhibitor, with IC₅₀ values of 2, 17, and 2 μM, respectively. Desoxypeganine can be used for alcohol abuse research.

HY-N2510

Myristicin Myristicine	5-HT Receptor	Phenylpropanoids Simple Phenylpropanols Source classification Plants Myristicaceae Myristica fragrans Houtt.
Myristicine act as a serotonin receptor antagonist, a weak monamine oxidase (MAO) inhibitor. Myristicine is the main component of nutmeg essential oil from Myristica fragrans Houtt. Myristicine abuse produce hallucinogenic effects, organ damage, deliriumand others.

HY-N7204

4-Hydroxyderricin	Monoamine Oxidase Dopamine β-hydroxylase	Structural Classification Monophenols Phenols Umbelliferae Angelica keiskei Plants
4-Hydroxyderricin, the major active ingredients of Angelica keiskei Koidzumi, is a potent selective MAO-B (Monoamine oxidase inhibitors) inhibitor with an IC₅₀ of 3.43 μM. 4-Hydroxyderricin also mildly inhibits DBH (dopamine β-hydroxylase) activity. 4-Hydroxyderricin has antidepressant activity.

HY-N1636

1-Methyl-2-nonyl-4(1H)-quinolone	Monoamine Oxidase	Alkaloids Quinoline Alkaloids Classification of Application Fields Disease Research Fields Neurological Disease Source classification Plants Rutaceae
1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective *MAO-B* (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC₅₀ of 12.1 μM.

HY-Y0265

Isatin Indoline-2,3-dione	Monoamine Oxidase Apoptosis	Alkaloids Indole Alkaloids Classification of Application Fields Disease Research Fields Cardiovascular Disease Neurological Disease Source classification Plants other families
Isatin (Indoline-2,3-dione) is a potent inhibitor of monoamine oxidase (MAO) with an IC₅₀ of 3 μM. Also binds to central benzodiazepine receptors (IC₅₀ against clonazepam, 123 μM). Also acts as an antagonist of both atrial natriuretic peptide stimulated and nitric oxide-stimulated guanylate cyclase activity. Shows effect on the serotonergic system.

Cat. No.	Product Name	Species	Source

HY-P71521

Rnls Protein, Mouse (His-SUMO)
Rnls; Renalase; EC 1.6.3.5; Monoamine oxidase-C; MAO-C; mMAO-C
Mouse E. coli

Cat. No.	Product Name

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

HY-14605BS

Rasagiline-13C3 mesylate racemic
Rasagiline-¹³C₃ (mesylate racemic) is a ¹³C-labeled Rasagiline mesylate racemic. Rasagiline mesylate racemic is a highly potent selective irreversible mitochondrial monoamine oxidase (MAO) inhibitor[1].

HY-Y0882S1

Hydroxylamine-d3 hydrochloride
Hydroxylamine-d₃ (hydrochloride) is the deuterium labeled Hydroxyamine hydrochloride[1]. Hydroxyamine hydrochloride is a selective monoamine oxidase (MAO) inhibitor used for inhibiting of platelet aggregation. Hydroxyamine hydrochloride is an intermediate of organic synthesis[2].

HY-101392S1

Harmane-d2

Harmane-d₂ is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-101392S

Harmane-d1

Harmane-d is the deuterium labeled Harmane. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively)[1][2][3][4].

HY-70057S1

Safinamide-d4-1

Safinamide-d₄-1 is deuterium labeled Safinamide. Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 µM) over MAO-A (IC50=580 µM)[1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 µM) than at resting (IC50=262 µM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].

HY-14280S

Entacapone-d10

Entacapone-d₁₀ is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].

HY-W015490S

1,4-Naphthoquinone-d6
1,4-Naphthoquinone-d₆ is the deuterium labeled 1,4-Naphthoquinone[1]. 1,4-Naphthoquinone is a potential pharmacophore for inhibition of both MAO (monoamine oxidase) and DNA topoisomerase activities, this latter associated with antitumor activity[2].

HY-B0534S1

Moclobemide-d4
Moclobemide-d₄ is deuterium labeled Moclobemide. Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase (MAO-A) inhibitor with an IC50 of 6.061 μM for hMAO-A[1].Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

MAO

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products